Interleukin-10-based therapy for inflammatory bowel disease
- PMID: 12880373
- DOI: 10.1517/14712598.3.5.725
Interleukin-10-based therapy for inflammatory bowel disease
Abstract
In recent years it has become clear that chronic inflammatory bowel disease (IBD), especially Crohn's disease (CD), is caused by a loss of tolerance against the autologous bacterial flora of the intestine. Tolerance against the indigenous flora requires optimal recognition of antigens by pattern recognition receptors and the presence of important regulatory cells and cytokines. Interleukin-10 (IL-10) has a major role in the regulatory network of cytokines controlling mucosal tolerance, and it is, therefore, not surprising that this cytokine is proposed as a potent anti-inflammatory biological therapy in chronic IBD. This review will discuss the characteristics of IL-10, its immunoregulatory properties in mice and humans, and the use of IL-10 as a treatment for CD. The review will summarise the clinical studies that have taken place and discuss the lessons learned from these trials. Finally, the advantages and disadvantages of promising new strategies of IL-10 treatment, including gene therapy and the use of genetically modified bacteria, will be discussed. Both novel therapies have been shown to be successful in animal models of disease, and clinical testing is currently underway. The future goal of IL-10 treatment should be focused on mucosal delivery and remission maintenance instead of remission induction. In conclusion, it can be said that despite the disappointing results of IL-10 therapy so far, there is still enough rationale for the use of IL-10 as an anti-inflammatory biological treatment in chronic IBD.
Similar articles
-
IL-10 and its related cytokines for treatment of inflammatory bowel disease.World J Gastroenterol. 2004 Mar 1;10(5):620-5. doi: 10.3748/wjg.v10.i5.620. World J Gastroenterol. 2004. PMID: 14991925 Free PMC article. Review.
-
Actobiotics as a novel method for cytokine delivery.Ann N Y Acad Sci. 2009 Dec;1182:135-45. doi: 10.1111/j.1749-6632.2009.05067.x. Ann N Y Acad Sci. 2009. PMID: 20074282
-
Biologic therapy for inflammatory bowel disease.Drugs. 2005;65(16):2253-86. doi: 10.2165/00003495-200565160-00002. Drugs. 2005. PMID: 16266194 Review.
-
Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.Eur J Immunol. 1996 Apr;26(4):934-8. doi: 10.1002/eji.1830260432. Eur J Immunol. 1996. PMID: 8625991
-
Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.J Gastroenterol. 2003 Mar;38 Suppl 15:59-62. J Gastroenterol. 2003. PMID: 12698874 Review.
Cited by
-
Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector.J Inflamm (Lond). 2005 Oct 31;2(1):13. doi: 10.1186/1476-9255-2-13. J Inflamm (Lond). 2005. PMID: 16259632 Free PMC article.
-
Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis.BMC Gastroenterol. 2013 Dec 6;13:165. doi: 10.1186/1471-230X-13-165. BMC Gastroenterol. 2013. PMID: 24314293 Free PMC article.
-
Strategies for targeting cytokines in inflammatory bowel disease.Nat Rev Immunol. 2024 Aug;24(8):559-576. doi: 10.1038/s41577-024-01008-6. Epub 2024 Mar 14. Nat Rev Immunol. 2024. PMID: 38486124 Review.
-
Unleashing the therapeutic potential of NOD-like receptors.Nat Rev Drug Discov. 2009 Jun;8(6):465-79. doi: 10.1038/nrd2783. Nat Rev Drug Discov. 2009. PMID: 19483708 Review.
-
Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis.PLoS One. 2016 May 6;11(5):e0154817. doi: 10.1371/journal.pone.0154817. eCollection 2016. PLoS One. 2016. PMID: 27152519 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
